← Eichor
Study identifier: NCT06629207 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Condition: Parkinson Disease · REM Sleep Behavior Disorder · Dementia, Lewy Body  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

This description comes directly from the study's public registry record.

Talk to the study team

Axel Rominger, Prof. Dr. med.  ·  +41 316322610  ·  axel.rominger@insel.ch

Franziska Strunz, PhD  ·  +41 316643022  ·  studies.nuk@insel.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Inselspital, University Clinic for Nuclear MedicineBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06629207